Genmab A (GMAB) Profit After Tax (QoQ) (2019 - 2026)
Powered by 
Analysis
Genmab A (GMAB) Profit After Tax (QoQ) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn |
| 10 | Genmab A | 2.23 Bn | 728.64 Mn | 1.07 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 471.70% |
| Sep 30, 2025 | 75.52% |
| Jun 30, 2025 | 172.31% |
| Sep 30, 2024 | 47.09% |
| Jun 30, 2024 | 105.73% |
| Mar 31, 2024 | 106.23% |
| Dec 31, 2023 | -244.72% |
| Sep 30, 2023 | 1,576.75% |
| Jun 30, 2023 | -52.27% |
| Dec 31, 2021 | -96.11% |
| Sep 30, 2021 | 583.86% |
| Jun 30, 2021 | -90.86% |
| Mar 31, 2021 | 262.87% |
| Dec 31, 2020 | 74,041,894.87% |
| Sep 30, 2020 | -100.00% |
| Jun 30, 2020 | -1.47% |
| Mar 31, 2020 | 65,921,687.71% |
| Dec 31, 2019 | -100.00% |
| Sep 30, 2019 | 5,872.23% |